JP2010524486A - β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 - Google Patents

β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 Download PDF

Info

Publication number
JP2010524486A
JP2010524486A JP2010504745A JP2010504745A JP2010524486A JP 2010524486 A JP2010524486 A JP 2010524486A JP 2010504745 A JP2010504745 A JP 2010504745A JP 2010504745 A JP2010504745 A JP 2010504745A JP 2010524486 A JP2010524486 A JP 2010524486A
Authority
JP
Japan
Prior art keywords
oligomer
catenin
seq
nucleotide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010504745A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010524486A5 (https=
Inventor
ヴォルム，イェスペル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Innovation Center Copenhagen AS
Enzon Pharmaceuticals Inc
Original Assignee
Santaris Pharma AS
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma AS, Enzon Pharmaceuticals Inc filed Critical Santaris Pharma AS
Publication of JP2010524486A publication Critical patent/JP2010524486A/ja
Publication of JP2010524486A5 publication Critical patent/JP2010524486A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2010504745A 2007-05-01 2008-04-30 β−カテニンを調節するためのＲＮＡアンタゴニスト化合物 Pending JP2010524486A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91537107P 2007-05-01 2007-05-01
US2324408P 2008-01-24 2008-01-24
PCT/EP2008/055365 WO2008132234A2 (en) 2007-05-01 2008-04-30 Rna antagonist compounds for the modulation of beta-catenin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014125205A Division JP2014209915A (ja) 2007-05-01 2014-06-18 β−カテニンを調節するためのＲＮＡアンタゴニスト化合物

Publications (2)

Publication Number Publication Date
JP2010524486A true JP2010524486A (ja) 2010-07-22
JP2010524486A5 JP2010524486A5 (https=) 2011-07-14

Family

ID=39926160

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010504745A Pending JP2010524486A (ja) 2007-05-01 2008-04-30 β−カテニンを調節するためのＲＮＡアンタゴニスト化合物
JP2014125205A Abandoned JP2014209915A (ja) 2007-05-01 2014-06-18 β−カテニンを調節するためのＲＮＡアンタゴニスト化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014125205A Abandoned JP2014209915A (ja) 2007-05-01 2014-06-18 β−カテニンを調節するためのＲＮＡアンタゴニスト化合物

Country Status (15)

Country Link
US (4) US20090005335A1 (https=)
EP (1) EP2152879B1 (https=)
JP (2) JP2010524486A (https=)
KR (1) KR20100024399A (https=)
CN (1) CN101842483A (https=)
AU (1) AU2008244211B2 (https=)
CA (1) CA2685444A1 (https=)
DK (1) DK2152879T3 (https=)
EA (1) EA018986B1 (https=)
ES (1) ES2399371T3 (https=)
IL (1) IL201865A0 (https=)
MX (1) MX2009011878A (https=)
NZ (1) NZ581200A (https=)
TW (1) TW200848077A (https=)
WO (1) WO2008132234A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015503608A (ja) * 2012-01-09 2015-02-02 ノバルティス アーゲー ベータ−カテニン関連疾患を処置するための有機組成物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152879B1 (en) * 2007-05-01 2012-11-14 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
US9040493B2 (en) 2009-07-15 2015-05-26 Santaris Pharma A/S RNA antagonists targeting GLI2 for the treatment of leukemia
DK3037538T3 (da) * 2010-07-06 2019-06-24 Dicerna Pharmaceuticals Inc Fremgangsmåder og sammensætninger til specifik inhibering af beta-catenin ved hjælp af dobbeltstrenget rna
EP3260540A1 (en) 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2013071161A1 (en) * 2011-11-11 2013-05-16 Enzon Pharmaceuticals, Inc. Compounds for the modulation of beta-catenin expression and uses thereof
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2013173652A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
CN104955952A (zh) * 2013-01-30 2015-09-30 弗·哈夫曼-拉罗切有限公司 Lna寡核苷酸碳水化合物缀合物
SG11201508925WA (en) 2013-05-01 2015-11-27 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
CN105164261B (zh) 2013-05-01 2022-03-18 莱古路斯治疗法股份有限公司 用于增强的细胞摄取的化合物和方法
WO2015026346A1 (en) 2013-08-22 2015-02-26 Hewlett Packard Development Company, L.P. Projective computing system
TWI657755B (zh) * 2013-12-30 2019-05-01 Philip Morris Products S. A. 包含隔熱可燃熱源之煙品
CA2937992A1 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
WO2018093919A1 (en) * 2016-11-15 2018-05-24 City Of Hope Methods for intracellular delivery and enhanced gene targeting
KR102713236B1 (ko) 2017-02-09 2024-10-04 페머시스 인크. 생분해성 시아노아크릴레이트를 포함하는 조성물 및 방법
EP3790972A1 (en) 2018-05-08 2021-03-17 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
WO2023102188A1 (en) * 2021-12-03 2023-06-08 Quralis Corporation Gapmer antisense oligonucleotides with modified backbone chemistries

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000872A1 (en) * 1999-06-25 2001-01-04 Isis Pharmaceuticals, Inc. Antisense modulation of beta catenin expression
WO2003031937A2 (en) * 2001-10-12 2003-04-17 Morphotek, Inc. Genetic hypermutability of plants for gene discovery and diagnosis
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US9045518B2 (en) 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
MXPA05011022A (es) 2003-04-13 2006-04-27 Enzon Pharmaceuticals Inc Profarmacos oligonucleotidos polimericos.
US20050136395A1 (en) * 2003-05-08 2005-06-23 Affymetrix, Inc Methods for genetic analysis of SARS virus
US20070009899A1 (en) * 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
AU2006291836B2 (en) 2005-09-15 2012-02-23 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-Bl00 expression
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
EP2023940B1 (en) 2006-05-05 2011-06-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
EP2076257A4 (en) 2006-09-15 2014-04-16 Belrose Pharma Inc POLYMER CONJUGATES WITH POSITIVELY LOADED PARTS
EP2090127A2 (en) 2006-10-30 2009-08-19 Nokia Corporation Method, apparatus and system providing operator controlled mobility for user equipment
EP2152879B1 (en) 2007-05-01 2012-11-14 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000872A1 (en) * 1999-06-25 2001-01-04 Isis Pharmaceuticals, Inc. Antisense modulation of beta catenin expression
WO2003031937A2 (en) * 2001-10-12 2003-04-17 Morphotek, Inc. Genetic hypermutability of plants for gene discovery and diagnosis
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANN SURG ONCOL, vol. 12, no. 9, JPN6013012203, 2005, pages 733 - 742, ISSN: 0002482597 *
CANCER RES, vol. 61, JPN6013012197, 2001, pages 6563 - 6568, ISSN: 0002482594 *
EUR J CANCER, vol. 40, JPN6013012201, 2004, pages 1441 - 1452, ISSN: 0002482596 *
J SURG RES, vol. 101, JPN6013012199, 2001, pages 16 - 20, ISSN: 0002482595 *
J THORAC CARDIOVASC SURG, vol. 127, JPN6013012194, 2004, pages 92 - 98, ISSN: 0002482593 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015503608A (ja) * 2012-01-09 2015-02-02 ノバルティス アーゲー ベータ−カテニン関連疾患を処置するための有機組成物

Also Published As

Publication number Publication date
WO2008132234A4 (en) 2009-07-09
US20090005335A1 (en) 2009-01-01
US8039446B2 (en) 2011-10-18
EA018986B1 (ru) 2013-12-30
US20120004288A1 (en) 2012-01-05
CA2685444A1 (en) 2008-11-06
EA200971013A1 (ru) 2010-04-30
IL201865A0 (en) 2011-08-01
CN101842483A (zh) 2010-09-22
ES2399371T3 (es) 2013-03-27
EP2152879B1 (en) 2012-11-14
KR20100024399A (ko) 2010-03-05
WO2008132234A2 (en) 2008-11-06
WO2008132234A3 (en) 2009-05-07
US20090203137A1 (en) 2009-08-13
TW200848077A (en) 2008-12-16
AU2008244211A1 (en) 2008-11-06
DK2152879T3 (da) 2013-02-18
NZ581200A (en) 2012-04-27
MX2009011878A (es) 2010-01-25
EP2152879A2 (en) 2010-02-17
JP2014209915A (ja) 2014-11-13
US7915401B2 (en) 2011-03-29
AU2008244211B2 (en) 2014-08-21
US20110086902A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
US8039446B2 (en) Compounds for the modulation of beta-catenin expression
US8450291B2 (en) RNA antagonist compounds for the modulation of PIK3CA expression
US20120295955A1 (en) Rna antagonist compounds for the modulation of her3
US20110124709A1 (en) Rna antagonists targeting gli2
US9506060B2 (en) LNA antisense oligonucleotides for the modulation of Myc expression
JP2011505798A (ja) Ｍｃｌ−１を調節するためのＲＮＡアンタゴニスト化合物
US8440809B2 (en) RNA antagonists targeting Hsp27
US20120232132A1 (en) Rna antagonists targeting gli2 for the treatment of leukemia
US20140323557A1 (en) Compounds for the modulation of beta-catenin expression and uses thereof
US20110224281A1 (en) Rna antagonists targeting hsp70-2
AU2014265070A1 (en) Rna antagonist compounds for the modulation of beta-catenin
WO2012066092A1 (en) Compounds for the modulation of aurora kinase a expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130719

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140218